Prophylactic cancer vaccines: development and challenges for HBV and HPV vaccines in Latin America
Laura Ximena Ramírez López, Martha Carnalla, Tonatiuh Barrientos‐Gutiérrez, Pierre Coursaget, Nubia Muñóz · Salud Pública de México · 2023
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Salud Pública de México · Instituto Nacional de Salud Pública · article · 2023
Abstract
Vaccines against hepatitis B virus (HBV) and human papillomaviruses (HPV) are two safe and highly effective vaccines that were developed at the end of the 20th century and can prevent human cancer. HBV vaccine prevents liver cancer, and HPV prevents cervical and other HPV-related cancers. Starting with the immunogen identification, 15 years were necessary to reach the industrial production of HBV vaccine, and 20 years, for the HPV vaccines. However, while HBV vaccines have been commercially available for over 40 years and are used in most countries, there are still significant challenges to achieve universal childhood immunization against hepatitis B.
Similarly, HPV vaccines have been commercially available for 17 years, and yet, countries with higher cervical cancer still have the lowest HPV vaccination rates. We describe the development of HBV and HPV vaccines and discuss the challenges to reaching equitable access to these vaccines in Latin America.
Open the resolved locator · 10.21149/15061
Metadata licence: OpenAlex metadata (CC0)